Amalgam Stock for Accredited Investors

By UpMarket Research  |  Last updated: July 2026

Amalgam is a private strategy platform that connects leaders, investors, athletes, public figures, and institutions across Africa, the Gulf, and beyond. It focuses on high-level convenings, strategic advisory, and connecting people and capital to unlock opportunities. [1]

Access to pre-IPO shares is available to accredited investors through UpMarket.

Latest Price
$167.36M
Last funding round, 01/03/23, Perplexity
UpMarket Estimate
$167M
Based on UpMarket valuation model
Previous Price
$290.09M
Estimated valuation

How to Invest in Amalgam Through UpMarket

Amalgam shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.

Step 01

Verify accredited investor status

Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.

Step 02

Create an UpMarket account

Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.

Step 03

Review available Amalgam offerings

Full offering memoranda and risk disclosures provided before any commitment is required.

Step 04

Complete subscription documents

Review and sign subscription agreement. All documents handled digitally through the platform.

Step 05

Fund your investment

Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.

Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.

${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.

Valuation Growth Over Time

Post-money valuation by round
Previous rounds Most recent
DateRoundPPS (split-adj.)Valuation
01/03/23 Last funding round $167.36M
Estimated valuation $290.09M

Why Investors Are Watching Amalgam

Growth Signal

Amalgam Rx reached $13.5M revenue in 2023, bootstrapped

Amalgam Rx reported $13.5M in revenue in 2023, with consistent growth since its 2016 launch. The company says it has raised $0, indicating it scaled without venture capital or outside funding.

Product Milestone

Catalio backed $20M credit for medical-grade AI rollout

Amalgam Rx said it secured a $20M credit investment from Catalio Capital Management to accelerate its Medical-Grade AI deployment. The funding points to a product push centered on regulated healthcare software.

Market Opportunity

Digital health platform targets pharma and providers

Catalio describes Amalgam as a software development platform that rapidly deploys custom digital products for pharma and healthcare providers. That positions the company in a large enterprise healthcare market with recurring software demand.

Interested in Amalgam stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.

Request access →

Amalgam Leadership Team

Ryan Sysko
CEO
Matti Prasad
CTO
Jennifer Main
COO

UpMarket Investment Curation Process

  • Full diligence on every offering

    UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.

  • Strategy, fees & legal reviewed in full

    We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.

  • Disciplined managers only

    We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.

  • Built around your objectives

    Our goal is to empower you to build a portfolio that best meets your individual investment objectives.

Ready to access institutional-grade private market investments? Unlock private markets

Amalgam Stock FAQ

No. As of March 2026, Amalgam is a private company and does not trade on any public stock exchange. Accredited investors can access Amalgam shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.

Amalgam does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.

Yes. Accredited investors can indicate interest in Amalgam shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.

Pre-IPO investments carry significant risks. Amalgam shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.

In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.

There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.

The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.

UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.

Amalgam is a private strategy platform connecting leaders, investors, athletes, public figures, and institutions across Africa, the Gulf, and beyond, with Amalgam Rx reaching $13.5M revenue in 2023 while bootstrapped at a $167M valuation — accredited investors can access Amalgam stock through UpMarket.

Invest in Amalgam Request access